Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis

Stephen E Borst1,4*, Jonathan J Shuster6, Baiming Zou5, Fan Ye2,4, Huanguang Jia2, Anita Wokhlu3,7 and Joshua F Yarrow2,4

Abstract

Background: Potential cardiovascular (CV) risks of testosterone replacement therapy (TRT) are currently a topic of intense interest. However, no studies have addressed CV risk as a function of the route of administration of TRT.

Methods: Two meta-analyses were conducted, one of CV adverse events (AEs) in 35 randomized controlled trials (RCTs) of TRT lasting 12 weeks or more, and one of 32 studies reporting the effect of TRT on serum testosterone and dihydrotestosterone (DHT).

Results: CV risks of TRT: Of 2,313 studies identified, 35 were eligible and included 3,703 mostly older men who experienced 218 CV-related AEs. No significant risk for CV AEs was present when all TRT administration routes were grouped (relative risk (RR) = 1.28, 95% confidence interval (CI): 0.76 to 2.13, \( P = 0.34 \)). When analyzed separately, oral TRT produced significant CV risk (RR = 2.20, 95% CI: 1.45 to 3.55, \( P = 0.015 \)), while neither intramuscular (RR = 0.66, 95% CI: 0.28 to 1.56, \( P = 0.32 \)) nor transdermal (gel or patch) TRT (RR = 1.27, 95% CI: 0.62 to 2.62, \( P = 0.48 \)) significantly altered CV risk. Serum testosterone/DHT following TRT: Of 419 studies identified, 32 were eligible which included 1,152 men receiving TRT. No significant difference in the elevation of serum testosterone was present between intramuscular or transdermal TRT. However, transdermal TRT elevated serum DHT (5.46-fold, 95% CI: 4.51 to 6.60) to a greater magnitude than intramuscular TRT (2.20-fold, 95% CI: 1.74 to 2.77).

Conclusions: Oral TRT produces significant CV risk. While no significant effects on CV risk were observed with either injected or transdermal TRT, the point estimates suggest that further research is needed to establish whether administration by these routes is protective or detrimental, respectively. Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route, as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies.

Keywords: Testosterone, DHT, Cardiovascular disease trials, Random effects, Meta-analysis

Background

Testosterone replacement therapy (TRT) is being utilized at a rapidly increasing rate, with 1.6 billion dollars in sales in the US in 2011 [1]. Proven benefits for older men with low testosterone (T) levels include increases in muscle strength, exercise capacity, bone mineral density (BMD), libido and insulin sensitivity [2,3]. Meta-analysis through 2010 [4-6] confirmed three adverse events resulting from TRT: 1) polycythemia, 2) an increased number of prostate-related events, and 3) a small reduction in high density lipoprotein (HDL) cholesterol. Prostate events consist of the combined incidence of elevated prostate-specific antigen (PSA), prostate biopsy necessitated by results of digital rectal exam, increased urinary symptoms and prostate cancer [4]. A meta-analysis by Calof et al. shows no evidence that TRT increases prostate cancer (odds ratio = 1.09 with no trend toward significance), when considered as an independent outcome [4]. However, the cardiovascular (CV) risk of TRT is controversial [5,6].
Several recent reports have raised the concern that TRT may produce CV risks. In their randomized controlled trial (RCT) of transdermal T gel administration, Basaria et al. reported a very high incidence of CV adverse events (AEs) in treated subjects (21%) compared to placebo (5%) resulting in cessation of the trial [7]. More recently, Vigen et al., in a retrospective study of 8,709 hypogonadal men with a history of recent coronary angiography, reported a higher risk of the combined endpoints of myocardial infarction (MI), stroke and all-cause mortality in those who received any form of TRT (25.7%) compared to those who did not (19.9%) [8]. Another observational study by Finkle et al. evaluated 55,000 patients and reported a more than two-fold greater risk of MI in men who had received a TRT prescription [9]. Similarly, a meta-analysis by Xu et al. of CV AEs in 27 RCTs administering TRT (reported through 2012) found that TRT produced a significantly greater number of CV AEs in TRT-treated participants compared to placebo (odds ratio (OR) 1.54, 95% CI 1.09 to 2.18) and also made the disturbing observation that these AEs were under-reported in industry-sponsored studies [10]. However, the statistical methods employed in the latter study were not appropriate for low event-rate meta-analysis [11]. In contrast, Corona et al. published a meta-analysis of 75 studies of TRT using less stringent inclusion criteria and found no evidence of CV risk (OR = 1.07 for all CV AEs; OR = 1.01 for serious CV AEs). In response to these reports, in 2014, the US Food and Drug Administration [13], the US Veteran’s Administration [14] and the Endocrine Society [15] have all issued advisories regarding CV AEs resulting from TRT.

In contrast with the above reports, some of which indicate that TRT may be associated with [8,9] or may cause [7,10] increased CV events, there is an extensive literature supporting the CV benefits of adequate levels of endogenous T and TRT. In older men, low T is associated with increased CV risk and increased all-cause mortality [16]. Several studies have shown that TRT is beneficial in populations of older men with CV disease. English et al. have shown that TRT improves exercise capacity in men with angina [17]. In addition, Toma and colleagues [18] have published a meta-analysis demonstrating improved New York Heart Association (NYHA) class, six minute walk time and peak oxygen consumption after TRT in men with systolic heart failure [18]. Furthermore, in a large retrospective cohort study of more than 6,000 intramuscular TRT users and matched controls, Baillargeon et al. reported no increase in CV events in myocardial infarction hospitalization rates in all TRT-treated subjects and reduced rates in those who were in the quartile with the highest risk factors for CV disease [19].

One potential explanation for these apparently conflicting observations is that the CV risk/benefit ratio may vary by the route of TRT administration. Testosterone can be administered by intramuscular injection of long-acting T esters, transdermally by patch or gel and orally as testosterone undecanoate (TU). Different routes of administration are typically associated with different doses, different time courses of serum androgen elevation and different relative levels of dihydrotestosterone (DHT) relative to testosterone. Transdermally and orally administered T are exposed to a high degree of 5-alpha reductase activity present in the skin [20] and liver [21], respectively, possibly increasing serum DHT relative to testosterone, which may affect CV risk. Shores et al. recently reported that serum DHT is independently and positively associated with incident CV disease [22], incident stroke [23], and all-cause mortality [22]. In contrast, in a cohort of 1,032 elderly men followed for a median of nine to ten years, neither circulating T nor free T were associated with the latter adverse outcomes.

The main purpose of this meta-analysis was to assess whether the incidence of CV events is affected by the mode of TRT administration. Our secondary purpose was to determine if there is a differential elevation of T versus DHT based on route of TRT administration. We postulate that the latter may be a potential mechanism for differential CV effects.

Methods

Data sources and searches

This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [see Additional file 1]. Two expert authors searched for and selected the studies, agreed upon the eligibility of each study and extracted information from the selected trials (SB, FY). We systematically searched PubMed until 31 May 2014 using two search strategies: 1) (“testosterone” or “androgen”) and (random*) and 2) “testosterone” and “clinical trials”. Studies of men, published in English were selected and the search was supplemented by a search of the World Health Organization trial registry and by a manual search of bibliographies of identified studies (SB and FY). To identify studies reporting the elevation of serum T and DHT following TRT, we performed a supplemental search using the terms: “testosterone” and “DHT” and (“injection” or “gel” or “patch” or “oral”) that included all TRT clinical trials in men because few studies report DHT concentrations before and after TRT.

Study selection

CV risks following TRT

We included only placebo-controlled RCTs of TRT that reported CV related events for both the TRT and placebo arms. We excluded trials where testosterone secretion was experimentally suppressed prior to initiation of TRT.
because these studies do not have a true placebo group. In order to assess the long-term, rather than the acute, effects of TRT, we included only trials lasting 12 weeks or more. Initially, we intended to exclude RCTs that only reported AEs necessitating study withdrawal, however this turned out to be a fine distinction and so we included any RCT that reported CV events by treatment arm. In order to ensure that we did not include more than one study using the same data set, we checked for duplication based on authorship, study description, number of participants, and participant characteristics. Where duplication occurred, we used the report containing the most comprehensive description of AEs.

**Elevation of serum T and DHT following TRT**

Few placebo-controlled RCTs report both serum T and DHT before and after treatment. For this reason, we broadened our search to include all TRT trials that reported both serum T and DHT, before and after treatment, regardless of study duration or whether the study was blinded. We have recently shown that commercially available methods for measuring DHT by immunoassay are invalid [24]. For this reason, we also excluded one study where DHT was measured by immunoassay [25]. We also removed any duplication of studies as described above.

**Outcome**

The primary outcome was composite CV events because we anticipated too few events to allow for analysis by individual event type. CV events were defined as anything reported as such in the original study. In cases where authors sent us a table of all AEs, we (SEB and AW - Cardiologist) defined CV AEs using International Statistical Classification of Disease (ICD) 10 codes [see Additional file 2]. CV events in individual studies are listed in Additional file 3. The secondary outcome was elevation of serum T and DHT following TRT administration by different routes (intramuscular, transdermal (patch or gel) or oral).

**Data extraction and quality assessment**

Data for CV AEs and elevation of serum T and DHT were extracted by trial arm by SB and FY. Event classification was checked by a cardiologist (AW). Reviewers (SB and FY) used an established tool to evaluate the quality of each trial [26] [see Additional file 4 and Additional file 5]. If the trial did not report CV AEs or did not do so by treatment arm, we contacted the authors twice by email to ask for additional information [see Additional file 6]. Studies were excluded if CV event incidence could not be determined with the above method.

**Statistical methods**

**CV events analysis**

It is important to note that this collection of studies involves low event-rate randomized binomial trials. Since the trials involve diverse interventions, random effects are mandatory, whether or not a Cochran Q test fails to reject homogeneity (Borenstein et al. [27], section titled ‘Model should not be based on the test for heterogeneity’). In addition, commonly used methods based on inverses of variance estimators such as the DerSimonian-Laird method are not valid in this arena. The Cochrane Handbook [28], section 16.9, states ‘Methods that should be avoided with rare events are the inverse-variance methods (including the DerSimonian and Laird (DL) [29] random-effects method). Xu et al. [10] used a fixed effects meta-regression with inverse variance weights in their previous meta-analysis, and as such, this was not an acceptable approach when event rates are low. Furthermore, compared with a random effects model, a fixed effects model makes the strong assumption that the true effect size for all studies is identical and the inference from a fixed effects model is conditional and limited to the studies included in the meta-analysis [30]. The methodology we employ is the sample size weighted random effects method of Shuster et al. [11], specifically designed for low event-rate meta-analysis, and which has been vetted on nearly 40,000 low event scenarios. Given the issues with low event-rate meta-analysis, ignored in Xu et al., it is critically important to reanalyze those data in this paper. Note that we employ RR, the estimate of the ratio of failure rates, rather than the OR, the ratio of the odds of failure. RR and OR are very similar when event rates are low, but RRs are far easier to understand.

**Analysis of serum T and DHT levels**

For laboratory levels, we used a minor modification of the patient weighted random effects method of Shuster [31], using the more conservative t-distribution (degrees of freedom = number of studies - 1) instead of the normal approximation. In our experience this is a better large sample approximation. Means are sample-weighted. The individual study fold changes were analyzed (not the ratio of the summary post-test estimate to the summary pre-test estimate).

**Results**

**Study selection and characteristics for analysis of CV risks**

The initial search yielded 2,313 publications, of which 197 were subjected to further scrutiny. As shown in Figure 1, we subsequently identified 35 unique publications of placebo-controlled RCTs of TRT in men that reported CV events and met our search criteria. The study design and patient characteristics across these trials are summarized in Table 1. The 35 studies of TRT include...
3,703 men, typically older than 45 years, with low T and/or chronic diseases. Of the 35 trials, 16 studies administered TRT intramuscularly, 15 transdermally (10 gel and 5 patch), and 4 orally. The mean duration of treatment was 11.9 months.

Risk of CV events based on route of TRT

Of the 3,703 subjects, 2,114 receiving TRT had 131 CV-related events (6.2%), while 1,589 receiving placebo had 87 (5.5%) CV-related events. Two trials were stopped early, one because of AEs in the TRT arm [7] and one because a beneficial effect of TRT was ‘not foreseeable’ [32]. Additional file 3 shows a comprehensive list of the type and severity of the 218 CV events (if specified) in the TRT and placebo groups.

As shown in Figure 2, among patients receiving any form of TRT, the estimated RR for CV events was 1.28 (95% CI 0.76 to 2.13, P = 0.34) which was not statistically significant. However, CV event rates varied by mode of TRT administration. Specifically, oral TRT resulted in a significant increase in CV events (estimated RR = 2.20, 95% CI 1.45 to 3.35, P = 0.015). In contrast, neither intramuscular TRT (estimated RR = 0.66, 95% CI 0.28 to 1.56, P = 0.32) nor transdermal (patch or gel) TRT (estimated RR = 1.27, 95% CI 0.62 to 2.62, P = 0.48) significantly affected CV events.

Re-analysis of Xu et al. [10]: Using the same patient-weighted method [31], the estimated relative risk for CV AEs is 1.59 (95% CI = 0.90 to 2.57), P = 0.059, not quite statistically significant, whereas Xu et al. [10] using inverse variance weighted methods (against the advice of the Cochrane Handbook), reported a point estimate of 1.54 (95% CI = 1.09 to 2.18).

Route of TRT and elevation of serum T and DHT Levels

As shown in Figure 3, the initial search yielded 419 publications, of which 56 were subjected to further scrutiny. We subsequently identified 31 unique publications that met our criteria and which included 1,176 men who received TRT (see Table 2). Elevation of serum DHT, but not T, was significantly affected by TRT administration mode (see Table 3). Specifically, intramuscular TRT elevated serum T and DHT to a roughly similar degree. In contrast, transdermal TRT elevated DHT to a significantly greater degree (5.46-fold, 95% CI 4.51 to 6.60) than intramuscular TRT (2.20-fold, (95% CI 1.74 to 2.77). Only four oral TRT studies were identified that reported both T and DHT, and the data were insufficient for statistical analysis. However, oral TRT appeared to produce a post-treatment serum T that was similar with other administration routes and very high post-treatment serum DHT values.

Figure 1 Selection process for placebo-controlled randomized clinical trials (RCTs) of testosterone replacement therapy (TRT) on CV events.
| Author/Year | Mode | Dose | Study duration | Age | Subjects in TRT group | Subjects in placebo group | Serum T at entry | Health status |
|-------------|------|------|----------------|-----|-----------------------|--------------------------|-------------------|---------------|
| Amory 2004 [32] | i.m. | 100 mg TE/week | 36 months | 71 ± 4 (SD) | 24 | 24 | 302 ± 48 (SD) ng/dL | hypogonadal |
| Aversa 2010 [33] | i.m. | 1,000 mg TU/12 week | 24 months | 58 ± 10 (SD) | 40 | 10 | 259 ± 48 (SD) ng/dL | hypogonadal |
| Borst 2014 [34] | i.m. | 125 mg TE/week | 12 months | 69.2 ± 8.0 (SD) | 31 | 29 | 264 ± 92 (SD) ng/dL | hypogonadal |
| Caminiti 2009 [35] | i.m. | 1,000 mg TU/8 week | 4.5 months | 66 to 76 | 35 | 35 | 230 ± 180 (SD) ng/dL | hypogonadal, heart failure |
| Ferrando 2002 [36] | i.m. | 100 mg TE/week | 6 months | 67 ± 3 (SD) | 7 | 5 | <480 ng/dL | eugonadal |
| Hackett 2014 [37] | i.m. | 1000 mg TU/6 to 12 weeks | 7.5 months | 18 to 80 | 97 | 102 | 301 ± 11 (SD) ng/dL | hypogonadal, type 2 diabetes |
| Hall 1996 [38] | i.m. | 250 mg TE/4 weeks | 9 months | 60.8 ± 9.7 (SD) | 17 | 18 | 458 ± 187 (SD) ng/dL | eugonadal, rheumatoid arthritis |
| Ho 2011 [39] | i.m. | 1,000 mg TU/10 to 14 weeks | 24 months | ≥40 | 60 | 60 | <345 ng/dL | low normal T |
| Hoyos 2012 [40] | i.m. | 1,000 mg TU/6 weeks | 4.5 months | 49 ± 12 (SD) | 33 | 34 | 388 ± 152 (SD) ng/dL | eugonadal, obese, sleep apnea |
| Kalichenko 2010 [41] | i.m. | 1,000 mg TU/6 to 12 weeks | 7.5 months | 49 to 53 | 113 | 71 | <345 ng/dL | low normal T, metabolic syndrome |
| Kenny 2004 [42] | i.m. | 200 mg TE/3 weeks | 3 months | 81 ± 5 (SD) | 6 | 5 | 410 ± 112 (SD) ng/dL | mild cognitive impairment |
| Sih 1997 [43] | i.m. | 200 mg TC/2 weeks | 12 months | 65 ± 7 (SD) | 17 | 15 | 233 ± 20 (SD) ng/dL | hypogonadal |
| Svartberg 2004 [44] | i.m. | 250 mg TE/4 weeks | 6 months | 64 ± 6.5 (SD) | 15 | 14 | 590 ± 164 (SD) ng/dL | eugonadal, COPD |
| Svartberg 2008 [45] | i.m. | 1,000 mg TU/6 to 12 weeks | 12 months | 69 ± 5 (SD) | 19 | 19 | 239 ± 54 (SD) ng/dL | hypogonadal |
| Sheffield-Moore 2011 [46] | i.m. | 100 mg TE/week | 5 months | 73 ± 8 (SD) | 8 | 8 | <500 ng/dL | eugonadal |
| Tan 2013 [47] | i.m. | 1,000 mg TU/weeks | 12 months | 53.8 ± 8.3 (SD) | 56 | 58 | <345 ng/dL | low normal T |
| *Basaria 2010 [7] | gel | 100 to 150 mg T/day | 6 months* | 74 ± 5 (SD) | 106 | 103 | 250 ± 57 (SD) ng/dL | hypogonadal, mobility limited |
| Brockenbrough 2006 [48] | gel | 100 mg T/day | 6 months | 58.9 ± 14.9 (SD) | 19 | 21 | 218 ± 64 (SD) ng/dL | hypogonadal, renal disease |
| Glintborg 2013 [49] | gel | 50 to 100 mg T/day | 6 months | 62 to 72 | 20 | 18 | <210 ng/dL | hypogonadal, obese |
| Hildreth 2013 [50] | gel | 25 to 50 mg T/day | 12 months | 66.6 ± 5.8 (SD) | 96 | 47 | 294 ± 38 (SD) ng/dL | hypogonadal |
| Jones 2011 [51] | gel | 60 mg T/day | 12 months | 37 to 77 | 108 | 112 | 265 ± 75 (SD) ng/dL | hypogonadal, metabolic syndrome |
| Kaufman 2011 [52] | gel | 20 to 80 mg T/day | 6 months | 53.6 ± 9.5 (SD) | 234 | 40 | mean = 294 ng/dL | hypogonadal |
| Kenny 2010 [53] | gel | 50 mg T/day | 12 to 24 months | 799 ± 7.3 (SD) | 69 | 62 | 380 ± 85 (SD) ng/dL | eugonadal, osteoporosis |
| Marin 1993 [54] | gel | 125 mg T/day | 9 months | 56.7 ± 2.2 (SD) | 11 | 10 | 434 ± 23 (SD) ng/dL | eugonadal, obese |
| Spitzer 2012 [55] | gel | 100 to 300 mg T/day | 3.5 months | 55.1 ± 8.3 (SD) | 70 | 70 | 248 ± 62 (SD) ng/dL | hypogonadal, erectile dysfunction |
| Srinivas-Shankar 2010 [56] | gel | 50 mg T/day | 6 months | 73.7 ± 5.7 (SD) | 138 | 136 | 313 ± 89 (SD) ng/dL | low normal T, frail |
| English 2000 [17] | patch | 5 mg T/day | 3 months | 69 ± 2 (SD) | 25 | 25 | 390 ± 22 (SD) ng/dL | eugonadal, stable angina |
| Malkin 2006 [57] | patch | 5 mg T/day | 12 months | 63.1 ± 10.7 (SD) | 37 | 39 | 400 ± 152 (SD) ng/dL | hypogonadal, heart failure |
| Merza 2005 [58] | patch | 5 mg T/day | 6 months | 63 ± 9 (SD) | 20 | 19 | 242 ± 95 (SD) ng/dL | hypogonadal |
| Nair 2006 [59] | patch | 5 mg T/day | 24 months | 61 to 72 | 27 | 31 | <200 ng/dL | bioavailable T <103 ng/dL |
| Snyder 2001 [60] | patch | 6 mg T/day | 36 months | 71.3 ± 5.8 (SD) | 54 | 54 | <475 ng/dL | hypogonadal |
| Chapman 2009 [61] | oral | 160 mg TU/day | 12 months | 78 ± 4 (SD) | 11 | 12 | 541 ± 35 (SD) ng/dL | eugonadal, undernourished |
Table 1 Characteristics of placebo-controlled randomized clinical trials of testosterone replacement therapy (TRT) reporting CV events (Continued)

| Study                        | Route | Dose               | Duration | Age Range | n  | Mean Serum T (SD) | Testosterone Status | COPD, Chronic Obstructive Pulmonary Disease |
|------------------------------|-------|--------------------|----------|------------|----|-------------------|---------------------|---------------------------------------------|
| Copenhagen study 1986 [62]   | oral  | 600 mg micronized T/day | 8 to 62 months | 24 to 79 | 134 | not measured | alcoholic cirrhosis |
| Emmelot-Vonk 2008 [63]      | oral  | 80 mg TU/day       | 6 months | 67.1 ± 5.0 (SD) | 120 | 316 ± 54 (SD) ng/dL | low normal T        |
| Legros 2009 [64]            | oral  | 80 to 240 mg TU/day | 12 months | 58.6 ± 5.7 (SD) | 237 | free T <7.5 ng/dL | hypogonadal         |

*Study was stopped early. COPD, chronic obstructive pulmonary disease; i.m., intramuscular; SD, standard deviation; T, testosterone; TC, testosterone cypionate; TE, testosterone enanthate; TU, testosterone undecanoate.
Discussion

This meta-analysis of 35 eligible studies and more than 3,700 patients receiving TRT is the largest consolidation of RCT data thus far. Our main finding is that no significant increase in CV event risk was noted among studies of various TRT administration routes when analyzed together. Further, when the risk of CV events was analyzed based on the mode of administration, only oral TRT was associated with elevated CV risk when compared with placebo. The increase in CV risk resulting from transdermal TRT and the decrease in CV risk seen with intramuscular TRT did not achieve statistical significance. A second important finding in this meta-analysis is that the oral and transdermal administration methods of TRT are associated with greater DHT elevations than intramuscular administration. Because there is emerging
data demonstrating an association between elevated DHT (rather than serum T) and adverse CV events, these two findings may have important implications for our current understanding of the mechanisms of CV risk in TRT recipients.

**Mode of administration and CV risk**

Our finding that there are varying CV risks based on the type of TRT formulation helps reconcile seemingly disparate observations across various studies regarding testosterone’s CV effects. While three prior meta-analyses suggested no significant increase in CV risk across TRT RCTs [4-6], a more recent meta-analysis by Xu et al. [10] indicated higher CV risk with TRT. The present meta-analysis is the most extensive thus far. Although we included all reported CV AEs in this meta-analysis, we have included newer studies exclusive to this review which may reflect less publication bias, more rigorous patient screening practices and more attention to the reporting of hard CV endpoints rather than nonspecific CV events that may have driven AE rates in previous studies.

The increased CV risk of the oral formulation subgroup is a novel finding in our analysis. While no significant effects on CV risk were observed with either injected or transdermal TRT, the point estimates suggest that further research is needed to establish whether administration by these routes is protective or detrimental, respectively. To the best of our knowledge, differing CV risk specific to varying testosterone formulations has not been previously reported.

**DHT elevation and increased CV risk**

The greater elevation of DHT that occurs with oral or transdermal TRT may be due to the high expression of 5-α reductase in skin [20] and liver [21] in comparison to lower 5-α reductase in skeletal muscle [89]. The finding of differential DHT elevation may be critical to our understanding of adverse CV risk, because elevated serum DHT (not elevated T) has recently been found to be associated with CV risk in several observational studies.

Shores et al. published two studies of 1,032 older men which reported significant associations between the serum DHT concentration and both the 10-year rate of incident ischemic stroke [23] and the 9-year rate of incident CV disease and all-cause mortality [16] (see Figure 4). Interestingly, similar relationships did not exist for serum total or free T, suggesting that CV risk resulting from TRT may result from the 5α-reduction of T to DHT. In both studies by Shores et al., the lowest risk was associated with a serum DHT concentration of approximately 60 ng/dL, while greater risk was associated with both higher and lower DHT concentrations.

In Figure 4, the left panel represents data from our meta-analysis showing the elevation of serum DHT with intramuscular, transdermal and oral TRT. In the center and right panels, we have superimposed that data on top
Table 2 Characteristics of testosterone replacement therapy (TRT) trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations before and after treatment

| Author/Year   | Study type  | Mode       | Dose            | Duration       | Age        | Subjects in TRT group | Serum T at entry | Health status                  |
|---------------|-------------|------------|-----------------|----------------|------------|-----------------------|------------------|-------------------------------|
| Amory 2004    | RCT         | i.m.       | 100 mg TE/week  | 36 months      | 71 ± 4 (SD) | 24                    | 302 ± 48 (SD) ng/dL | hypogonadal                   |
| Arver 1997    | open-label  | i.m.       | 266 mg TE/26 days | 3 weeks       | 58 ± 10 (SD) | 27                    | 121 ± 100 (SD) ng/dL | hypogonadal                   |
| Bhasin 2012   | RCT         | i.m.       | 125 mg TE/week  | 5 months       | 40 ± 7 (SD)  | 12                    | 519 ng/dL (mean)    | eugonadal                     |
| Borst 2014    | RCT         | i.m.       | 125 mg TE/week  | 12 months      | 69.2 ± 80 (SD) | 31                   | 264 ± 92 (SD) ng/dL | hypogonadal                   |
| Lakshman 2010 | RCT         | i.m.       | 125 mg TE/week  | 5 months       | 65.6 ± 4.3 (SD) | 11                  | 581 ± 168 (SD) ng/dL | eugonadal                     |
| Raynaud 2008  | open-label  | i.m.       | 250 mg TE/3 weeks | 12 months     | 41.8 ± 124 (SD) | 32                 | 43 ng/dL (mean)      | hypogonadal                   |
| Shubert 2003  | open-label  | i.m.       | 250 mg TE/3 weeks | 12 months     | 31.9 ± 2.5 (SD) | 14                  | 636 ng/dL ± 14 (SD)  | hypogonadal                   |
| Wang 2010     | open-label  | i.m.       | 750 mg TU/4 to 10 weeks | 21 months    | >18        | 117                   | 320 ng/dL ± 111 (SD) | low normal T                  |
| Brockenbrough 2006 | RCT | gel       | 10 mg T/day   | 6 months       | 58.9 ± 14.9 (SD) | 19 | 218 ± 64 (SD) ng/dL | hypogonadal, renal disease   |
| Cherier 2003  | RCT         | gel       | 50-100 mg T/day | 6 months       | 34 to 70     | 12                    | 320 ± 90 (SD) ng/dL  | low normal T                  |
| Chiang 2007   | RCT         | gel       | 50 mg T/day    | 3 months       | 20 to 75     | 17                    | 213 ± 158 (SD) ng/dL | hypogonadal                   |
| Dean 2004     | open-label  | gel       | 50 mg T/day    | 9 months       | 585 (mean)   | 257                   | 247 ng/dL (mean)     | hypogonadal                   |
| Di Luigi 2012 | open-label  | gel       | 50 mg T/day    | 1.25 month     | 31.3 ± 7.5 (SD) | 10                  | 72 ng/dL (mean)      | hypogonadal                   |
| Juang 2014    | RCT         | gel       | 100 mg T/day   | 3.5 months     | 24 to 51     | 14                    | 302 ± 37 (SD) ng/dL  | hypogonadal, osteoporosis     |
| Kenny 2010    | RCT         | gel       | 50 mg T/day    | 12 months      | 79.9 ± 7.3 (SD) | 69                  | 380 ± 179 (SD) ng/dL | eugonadal, osteoporosis       |
| Marin 1993    | RCT         | gel       | 125 mg T/day   | 9 months       | 56.7 ± 2.2 (SD) | 10                  | 455 ± 23 (SD) ng/dL  | eugonadal, obese              |
| Mazer 2005    | RCT         | gel       | 59 mg/day      | 2 weeks        | 52.4 ± 12.2 (SD) | 28                 | 226 ± 110 (SD) ng/dL | hypogonadal                   |
| Page 2011     | RCT         | gel       | 75 mg T/day    | 6 months       | >50         | 27                    | 204 ng/dL (mean)     | hypogonadal, BPH              |
| Swerdloff 2000 | open-label | gel       | 100 mg T/day   | 3 months       | 51.3 (mean)  | 76                    | 280 ng/dL (mean)     | hypogonadal                   |
| Wang 2000     | no placebo group | gel | 100 mg T/day   | 2 weeks        | 26 to 59     | 10                    | 179 ± 41 (SD) ng/dL  | hypogonadal                   |
| Wang 2011     | open-label  | gel       | 60 mg T/day    | 4 months       | 51.5 ± 12.7 (SD) | 135                | 215 ± 84 (SD) ng/dL  | hypogonadal                   |
| Ahmed 1988    | no placebo group | patch | 15 mg T/day    | 6 to 8 weeks   | 34 to 54     | 5                     | 45 ± 12 (SD) ng/dL   | hypogonadal                   |
| Bals-Patch 1988 | not stated | patch 10 to 15 mg T/day | 14 months | 31 to 37     | 7                     | 189 ng/dL (mean)    | hypogonadal                   |
| Behre 1999    | open-label  | patch     | 2.4 to 3.6 mg T/day | 7 years       | 35.9 ± 98 (SD) | 11                  | 147 ± 37 (SD) ng/dL  | hypogonadal                   |
| Cunningham 1989 | placebo-controlled | patch | 15 mg T/day    | 8 weeks        | 33 to 66     | 12                    | 43 ± 11 (SD) ng/dL   | hypogonadal                   |
| Mazer 2005    | open-label  | patch     | 5 mg T/day     | 2 weeks        | 28 to 71     | 28                    | 215 ± 110 (SD) ng/dL | hypogonadal                   |
| Melke 1992    | not stated  | patch     | 12.6 mg T/day  | single dose    | 24 to 66     | 6                     | 161 ± 27 (SD) ng/dL  | hypogonadal                   |
| Raynaud 2008  | open-label  | patch     | 2.5 mg T/day   | 12 months      | 40.7 ± 105 (SD) | 131                | 43 ng/dL (mean)      | hypogonadal                   |
| Franchimont 1978 | oral       | 120 to 240 mg TU/day | 9 weeks      | 16 to 51     | 10                    | 120 ng/dL (mean)    | hypogonadal                   |
Table 2 Characteristics of testosterone replacement therapy (TRT) trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations before and after treatment (Continued)

| Study (Year, Ref.) | Design | Route | Dosage | Duration | Baseline | Post-treatment | Status |
|--------------------|--------|-------|--------|----------|----------|----------------|--------|
| Roth 2011 [87]     | open-label | oral | 400 mg TU/day | 1 day | 18 to 52 | 405 ± 14 (SD) ng/dL | eugonadal |
| Schubert 2003 [69] | open-label | oral | 160 mg TU/day | 12 months | 34.5 ± 3.9 (SD) | 63.6 ng/dL ± 14 (SD) | hypogonadal |
| Van Coevorden 1986 [88] | RCT    | oral | 240 mg TU/day | 12 weeks | 40 ± 11 (SD) | 161 ± 86 (SD) ng/dL | hypogonadal, renal insufficiency |

BPH, benign prostate hyperplasia; RCT, randomized clinical trial; SD, standard deviation; TE, testosterone enanthate; TU, testosterone undecanoate.
| Route of administration | Number of studies | Pre-treatment T (nmol/L) (95% CI) | Post-treatment T (nmol/L) (95% CI) | Pre-Post treatment fold increase in T (95% CI) | Pre-treatment DHT (nmol/L) (95% CI) | Post-treatment DHT (nmol/L) (95% CI) | Pre-Post treatment fold increase in DHT (95% CI) |
|-------------------------|------------------|-----------------------------------|-----------------------------------|-----------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------------|
| Intramuscular           | 8                | 9.27 (5.68 to 12.85)              | 23.11 (15.38 to 34.72)            | 2.91 (2.19 to 3.86)                           | 1.02 (0.69 to 1.34)              | 1.62 (1.2 to 2.19)                  | 2.20 (1.74 to 2.77)                   |
| Transdermal (patch and gel) | 20              | 7.28 (6.09 to 8.42)               | 16.69 (12.62 to 21.98)            | 2.53 (1.83 to 3.50)                           | 0.99 (0.78 to 1.20)              | 3.43 (2.37 to 4.98)                  | 5.46 (4.51 to 6.60)                   |
| Gel                     | 13               | 8.90 (7.67 to 10.13)              | 18.3 (15.18 to 23.12)             | 1.98 (1.70 to 2.30)                           | 1.19 (0.93 to 1.46)              | 3.81 (2.57 to 5.63)                  | 5.12 (4.07 to 6.45)                   |
| Patch                   | 7                | 4.20 (2.78 to 5.23)               | 9.73 (4.01 to 23.62)              | 4.43 (2.99 to 6.54)                           | 0.62 (0.36 to 0.88)              | 2.16 (0.68 to 6.87)                  | 6.61 (3.08 to 14.16)                  |
| Orala                   | 4                | 6.66 (5.18 to 8.14)               | 21.88 (15.48 to 30.62)            | 3.24 (2.47 to 4.19)                           | 0.70 (0.54 to 0.88)              | 3.74 (2.38 to 5.83)                  | 5.35 (3.73 to 7.57)                   |

| Pre-treatment T (nmol/L) (95% CI) | Post-treatment T (nmol/L) (95% CI) | Pre-Post treatment fold increase in T (95% CI) | Pre-treatment DHT (nmol/L) (95% CI) | Post-treatment DHT (nmol/L) (95% CI) | Pre-Post treatment fold increase in DHT (95% CI) |
|-----------------------------------|-----------------------------------|-----------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------------|
| 1405 (29, 56, 41)                | 592 (570, 76, 1496)               | 4.80 (2.99 to 6.54)                           | 1.00 (0.78 to 1.20)              | 3.43 (2.37 to 4.98)                  | 5.46 (4.51 to 6.60)                   |

*Effects of oral TRT on T and DHT concentrations were not statistically analyzed because only four studies were identified that met our a priori inclusionary criteria, which resulted in insufficient data. For oral studies, the mean and individual values for each of the four studies are listed. Transdermal (patch or gel) TRT produces a greater elevation of serum DHT than intramuscular TRT. Means are adjusted for sample size.
of the previously published data from the two papers by Shores et al. Taken together, these data appear to indicate that intramuscular TRT elevates the serum DHT concentration into a range that is associated with reduced CV disease (CVD) and stroke risks. In contrast, transdermal and oral TRT appear to elevate serum DHT into a range that is associated with unchanged CVD risk and increased ischemic stroke risk.

Limitations
Reporting of AEs may be open to interpretation and so may vary somewhat among trials. Using the most serious CV events (stroke, myocardial infarction, and CV-related death) might be more unambiguous. Because of very long follow-up periods, such events are common enough to assess in observational studies [16,22,23]. However, due to shorter study duration, serious CV events are not common enough to study in clinical trials of TRT. As a result, our analyses are based on all CV events, serious or not.

The data on oral TRT must be interpreted with caution, since only four studies met the inclusion criteria. Of those, two had very low rates of CV events in both the treated and placebo groups [61,64] and one study had very high post-treatment serum T concentrations [32], possibly due to the presence of liver disease in the study subjects. The latter study was not included in the analysis of TRT-induced elevations of T/DHT because DHT was not measured. However, among the four studies analyzed for T/DHT, there was considerable variation in serum concentrations. Variation may result from the fact that serum T concentrations are not sustained following oral TRT and the time of blood acquisition is therefore critical.

Two studies included in the analysis of CV risk were stopped early. One study of oral TRT was stopped because of lack of evidence for efficacy unrelated to CV [32] and one study of gel TRT was stopped early for excess CV events in the group receiving testosterone [7]. The first study, whose stopping was uninfluenced by CV, has no bias associated with early stopping. The second, may actually be associated with a slight bias estimate away from the null, actually strengthening the null conclusion. There is no way to adjust for this without serial patient level data and the exact stopping rules used.

Interpretation of the data on TRT-induced elevations of T and DHT may be limited by the fact that DHT was assayed by several methods in the included studies. The latter include mass spectroscopy (MS) based methods and various radioimmunoassays (RIAs). MS-based assays provide highly accurate measurements of DHT. RIAs are specific for DHT [90] but the values are somewhat higher than those obtained with MS-based assays [91]. The enzyme-linked immunosorbant assay (EIA) for DHT is not valid as we have recently shown [24] and studies using this method were excluded. The current analysis is based on clinical trials that have a high rate of compliance. An additional limitation in extending our findings to a clinical setting is that compliance may be lower. Schoenfeld et al. have shown that TRT gel adherence is only 37.4% at six months [92]. Similarly, Donatucci et al. [93] reported that at three months, adherence to transdermal TRT was 52% and adherence to injected TRT was 32%.
Potential cardiovascular benefits of testosterone

Although this paper encompasses a discussion of adverse CV risk of TRT, assessment of the CV risk–to-benefit should be considered. Numerous studies have demonstrated positive CV effects of TRT. English et al. [17] have shown that, in men with stable angina, treatment with low-dose T (5 mg/day by patch) for 12 weeks caused a significant 17% increase in time to 1-mm ST segment depression during treadmill exercise testing. Stout et al. [94] have shown that TRT administration to men with chronic heart failure increases maximal oxygen consumption (VO2max) and improves physical performance. Toma et al. [18] published a meta-analysis of the four studies showing that TRT improved exercise capacity in heart failure patients. Empen et al. [95] reported that T deficiency is associated with impaired arterial flow-mediated dilation (FMD), a marker of vascular endothelial function. Cardiovascular improvement with TRT is thought to result from increased coronary blood flow, peripheral vasodilation, positive remodeling of skeletal muscle and reduced insulin resistance, without marked effects on left ventricular ejection fraction [18].

Conclusions

The potential CV risks of TRT are currently being debated. This updated meta-analysis indicates oral TRT produces increased CV risk, while TRT administered by all routes may cause an increase in CV adverse events, but the effect is not statistically significant. On the latter point, a definitive answer awaits further clinical trials. More studies are also needed to assess whether increased CV risk occurs with the transdermal formulations and decreased CV risk with the intramuscular formulation. This early indicator that intramuscular T may be safer than transdermal TRT may be surprising, considering that intramuscular TRT doses are typically several-fold higher than transdermal doses. However, our data indicate that transdermal TRT produces a significantly greater elevation of serum DHT than intramuscular T, possibly due to the expression of 5-alpha reductase in the skin. Interestingly, serum DHT concentrations following intramuscular TRT correspond to DHT levels that are associated with reduced CV risk in other large observational studies, suggesting that: 1) CV risks of TRT administration may result from excessive elevation of serum DHT; and 2) intramuscular TRT may produce less CV risk than transdermal or oral TRT. Given our unique findings, future RCTs, meta-analyses and retrospective database studies evaluating the health risks associated with TRT should carefully control for the change in serum DHT and evaluate the TRT administration route as potential confounding factors in their data analysis.

Additional files

Additional file 1: PRISMA 2009 Checklist.
Additional file 2: ICD 10 codes for cardiovascular disease.
Additional file 3: Listing of CV events in RCTs selected for analysis of CV events.
Additional file 4: Quality assessment for RCTs reporting the effect of TRT on CV events.
Additional file 5: Quality assessment for trials reporting elevation of serum T and DHT following TRT.
Additional file 6: Inclusion of RCTs for analysis of CV events following attempts to obtain additional information from authors.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SEB participated in study conception and design, performed searches, contacted authors for additional information and drafted the manuscript. JJS and BZ performed statistical analysis and participated in revisions of the manuscript. FY performed searches, contacted authors for additional information, and participated in revisions of the manuscript. HJ participated in revision of the manuscript. AW assessed descriptions of cardiovascular events and participated in revisions of the manuscript. JY participated in study conception and design and in revisions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was partially supported by a VA Merit Award to SEB and by NIH grant 1UL1TR000064 from the National Center for Advancing Translational Sciences.

Author details

1Geriatric Research, Education and Clinical Center, Malcolm Randall VA Medical Center, 1601 SW Archer RD, Gainesville, FL 32605-1197, USA.
2Research Service, Malcolm Randall VA Medical Center, Gainesville, FL, USA.
3Medicine Service, Malcolm Randall VA Medical Center, Gainesville, FL, USA.
4Department of Applied Physiology & Kinesiology, University of Florida, Gainesville, USA.
5Department of Biostatistics, University of Florida, Gainesville, USA.
6Department of Health Outcomes and Policy, University of Florida, Gainesville, USA.
7Department of Medicine-Car Cardiovascular Division, University of Florida, Gainesville, USA.

Received: 9 September 2014 Accepted: 14 October 2014
Published online: 27 November 2014

References

1. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S: Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013, 9:414–424.
2. Traczk MJ, Sidiras K, Bolona ER, Haddad RM, Kennedy CC, Uruga MV, Caples SM, Enwin PI, Montori VM: Testosterone use in men and its effects on bone health: A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metabol 2006, 91:2011–2016.
3. Traish AM: Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids 2014, 88:117–126.
4. Calif OA, Singh AR, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451–1457.
5. Fernandez-Balsells MM, Murad MH, Lane M, Lampropoulos JF, Albuquerque F, Mullan RJ, Agninal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Enwin PI, Bhasin S, Montori VM: Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:2560–2575.
6. Haddad RM, Kennedy CC, Caples SM, Traczk MJ, Bolona ER, Siders K, Uruga MV, Enwin PI, Montori VM: Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:39–39.
randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51:1235–1241.

27. Borenstein M, Hedges LV, Higgins J, Rothstein HR: A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Meth 2010, 159–171.

28. Higgins JP, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Chichester, UK: Wiley Publications, 2011.

29. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–187.

30. Hedges LV, Vevea JL: Fixed- and random-effects models in meta-analysis. Psychol Methods 1998, 3:486–504.

31. Shuster JJ: Empirical vs natural weighting in random effects meta-analysis. Stat Med 2010, 29:1259–1265.

32. Armstrong PW, Ezekowitz JA: Endocrine Society Statement on the Risk of Cardiovascular Events in Men Receiving Testosterone Therapy. J Clin Endocrinol Metab 2014, 99:E753–E759.

33. Aversa A, Bruzzi P, Cappola A, Caprio A, Cancela J, Cavanagh P, Citterio G, De La Taille A, De Smet E, DeWitt D, Dorey F, Elia M, English K, Franco-Lobo L, Ford I, Frisina R, Gavriliadis M, Germany H, Goodwin JS, Gurtner GC, Haffner SM, Hambraeus L, Habib N, Haiduc V, Halim I, Hayashi M, Heiss G, Hinnenkamp S, Hoenig M, Horgan TJ, Hribar M, Hulme E, Hulth S, Imura J, Isidori A, Kevorkian A, Keverne A, Khaw K, Knoikus J, Konig H, Kovanen P, Krezel K, La Sala A, Landin O, Lapolla A, Largiarda D, Leclercq D, Leung W, Lim K, Liu G, Longcope C, Lox J, MacLennan A, Mahoney M, Maisonneuve P, Maisonneuve P, Malaisse L, Mantovani F, Markovic-Djordjevic N, Martini C, Marsh T, Massey S, Matsushita K, Matsuzawa Y, Matter C, Matysiak-Bukowska E, Mayorga J, Micic D, Miller J, Minassian AM, Mitchell J, Morigi G, Mostaghimi A, Mourey R, Muckenthaler M, Myint PK, Najjar S, Nessim V, Nuttall F, Oden A, Ong K, Ortlepp K, Oza S, Pickering J, Pollick F, Polyzoides M, Portincasa P, Prat F, Primignani M, Procaccini M, Puzos E, Quinton G, Quigley K, Ratcliffe J, Ravn H, Rebuffe-Scrive M, Reiter R, Rejas J, Remond E, Renous Y, Rios-Velazquez FL, Robichaud P, Roncalli J, Roseman M, Rosano G, Ruff L, Rundek T, Sambucetti L, Santoro N, Schini-Kerth V, Schnatz P, Seila J, Senders J, Setaro JA, Shachaf M, Siffert J, Simonetti JF, Solomon D, Souverijn P, Spadaro R, Spiller R, Steegers-Theunissen RP, Steffens F, Stocco D, Stranges S, Su R, Szabuniova M, Tanaka Y, Tataranni PA, Tchernof A, Tertnyk L, Tintore M, Todd M, Tomlinson B, Trabulsi E, Trivedi S, Tucke PG, Van Den Bosch M, Van Der Velden T, Van den Wyngaert T, Van Gaal L, Vanhoutte P, Vermeulen M, Verhaegen P, Vuillemot H, Vogeser M, Vukicevic M, Wang J, Wakefield L, Wallin A, Wang Y, Wasnich RD, Weir L, Wetterslev J, Whittaker M, Winkley K, Zamboni M, Zannad F, Ziegler J, Zito J.

34. Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Beek BW, Bethell D, Martin JS, Morrow M, Roesner S, Beggs LA, McCoy SC, Cannady DF, 7th, Shuster JJ: Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized controlled trial. Am J Physiol Endocrinol Metab 2014, 306:E433–E442.

35. Campini G, Volterrani I, Iellamo F, Mazzi M, Massaro R, Micheli M, Mammoliti P, Miki M, Mires A, Morano GM: Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009, 54:919–927.

36. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkinson C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ: Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002, 282:E661–E667.

37. Hackett G, Cole N, Bhattacharya A, Pasta M, Sambucetti L, Sattler A, Scharf A, A Blast Study Group: The response to testosterone undeacaenide in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014, 68:203–215.

38. Hall GM, Larbre JP, Spector TD, Perry LA, Da Silva JA: A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996, 35:568–573.

39. Ho CC, Song TS, Low WY, Ng CJ, Kho EM, Lee VK, Zainuddin ZM, Tan HM: A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012, 110:260–265.

40. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY: Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial. Eur J Endocrinol 2012, 167:511–514.

41. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F: Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012, 5:315–321.

42. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S: Testosterone treatment improves angina threshold in men with chronic heart failure a double-blind, placebo-controlled randomized study. J Am Coll Cardiol 2009, 54:919–927.

43. Keverne E, Khaw K, Knoikus J, Konig H, Kovanen P, Krezel K, La Sala A, Landin O, Lapolla A, Largiarda D, Leclercq D, Leung W, Lim K, Liu G, Longcope C, Lox J, MacLennan A, Mitchell J, Morigi G, Mostaghimi A, Mourey R, Rundek T, Sambucetti L, Schini-Kerth V, Schnatz P, Seila J, Senders J, Setaro JA, Shachaf M, Siffert J, Simonetti JF, Tertnyk L, Tintore M, Todd M, Tomlinson B, Trabulsi E, Trivedi S, Wang Y, Wakefield L, Wallin A, Wang Y, Wasnich RD, Weir L, Wetterslev J, Whittaker M, Winkley K, Zannad F, Ziegler J, Zito J.

44. Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R: Increased risk of non-fatal myocardial infarction and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab 2014, 99:2050–2058.

45. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R: Decline of plasma 5alpha-dihydrotestosterone levels improves body composition and BMD in the hip. Int J Obes 2004, 28:378–387.

46. Svartberg J, Aslaksen L, Halvorsen A, Sundsfjord J, Jorde R: Testosterone treatment in elderly men with subnormal plasma testosterone and high DHT levels. Andrologia 2008, 40:298–302.
46. Sheffield-Moore M, Dillon EL, Casperon SL, Gilkinson CR, Padison-Jones D, Durham WM, Grady JJ, Urban RJ: A randomized pilot study of monthly cycled testosterone replacement or continuous testosterone replacement versus placebo in older men. J Clin Endocrinol Metab 2011, 96:E1831–E1837.

47. Tan WS, Low WT, Ng CJ, Tan WK, Tong SF, Ho C, Khoo EM, Lee G, Lee BC, Lee Y, Tan HM: Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int 2013, 111:1130–1140.

48. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ: Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006, 47:251–262.

49. Ginting D, Christensen LL, Kueming T, Larsen R, Brixen K, Hougaard DM, Richardsen B, Bruun JM, Ansen M: Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men. Mediators Inflamm 2013, 2013:539156.

50. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura N, Daboo M, Piper V, Remagen P, Walsh J, Wilt TJ: Testosterone and sex hormone binding globulin levels and quality of life in men with hypogonadism: a 52 week, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2013, 98:1891–1900.

51. Jones TH, Aner S, Behere HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowsow A, Howland JF, Channer KS: TESTIM® Investigators: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828–837.

52. Kaufman JM, Miller MG, Gawein JL, Fitzpatrick S, McWhirter C, Brennan JJ: Efficacy and safety of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011, 8:2079–2089.

53. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D: Effects of transdermal testosterone on bone in adult and older men. J Clin Endocrinol Metab 2012, 97:1749–1759.

54. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, Oldham JA, Wu FC: Oral testosterone replacement in symptomatic hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007, 19:563–568.

55. Spitzer M, Basaria S, Travison TG, Davda MN, Palesy A, Cohen B, Mazer NA, Knapp PE, Hank J, Lakshman KM, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brieler L, Eder R, Elmi A, Bhasin G, Collins L, Singh R: The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010, 95:3955–3964.

56. Raynaud JP, Legros JJ, Rollet J, Auges M, Bunouf P, Soumac M, Fiet J: Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. J Steroid Biochem Mol Biol 2008, 109:168–176.

57. Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F: Osteopetrosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003, 60:21–28.

58. Westing C, Harrett M, Mobs K, Swerdloff RS: Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 2010, 31:457–465.

59. Cheung YS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, Liao CH: Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007, 19:411–417.

60. Dean JD, Camiee C, Rodzulla J, Smith T: Long-term effects of testis(r): 1% testosterone gel in hypogonadal men. Rev Urol 2004, 6:522–529.

61. Di Luigi L, Sly P, Avens A, Migliaccio S, Bianchi S, Boverone F, Romanelli F, Lenzi A: Concerns about serum androgens monitoring during testosterone replacement treatments in hypogonadal male athletes: a pilot study. J Sex Med 2007, 4:873–886.

62. Jiang YS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, Liao CH: Transdermal testosterone gel increases serum testosterone levels in hypogonadal men: a randomized controlled trial. J Sex Med 2014, 11:563–573.

63. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B, BS RN: Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005, 2213–2226.

64. Page ST, Hirano L, Gilchrist J, Digné M, Arroyo JK, Marck BT, Matsumoto AM: Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011, 186:191–197.

65. Swerdloff RS, Wang C, Cunningham G, Dobs A, Ironmannes A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2005, 88:4505–4510.

66. Wang C, Berman N, Longstreth J, Chuappaco B, Hull H, Steiner B, Faulkner S, Dudley RE, Swerdloff RS: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000, 85:964–969.

67. Wang C, Ilani N, Aner S, Mactahlan RI, Soult S, Watson K: Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011, 74:386–404.
81. Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M, Demers LM: Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988, 66:546–551.
82. Bals-Pratsch M, Langer K, Place VA, Nieschlag E: Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol 1988, 118:7–13.
83. Behe H, von Eckardstein S, Kiesch S, Nieschlag E: Long-term substitution therapy of hypogonadal men with transcutaneous testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999, 50:629–635.
84. Cunningham GR, Cordero E, Thornby JI: Testosterone replacement with transdermal therapeutic systems: physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989, 261:2525–2530.
85. Mekle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992, 74:623–628.
86. Franchimont P, Kicovic PM, Mattei A, Roulier R: Effects of oral testosterone undecanoate in hypogonadal male patients. Clin Endocrinol (Oxf) 1978, 9:313–320.
87. Roth MY, Dudley RE, Hull L, Leung A, Christenson P, Wang C, Swerdloff R, Amory JK: Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5alpha-reductase by finasteride. Int J Androl 2011, 34:541–547.
88. van Coevorden A, Stolear JC, Dhaene M, van Herweghem JL, Mockel J: Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 1986, 26:48–54.
89. Yarrow JF, McCay SC, Borst SE: Intracrine and myotrophic roles of Salph-reductase and androgens: a review. Med Sci Sports Exerc 2012, 44:818–826.
90. Stanczyk FZ, Azen CG, Pike MC: Effect of finasteride on serum levels of androstenedione, testosterone and their Salpha-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol 2013, 138:10–16.
91. Wang C, Shiawshi S, Leung A, Baravanian S, Hull L, Goh V, Lee PW, Swerdloff RS: Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: interference and comparison with established methods. Steroids 2008, 73:1345–1352.
92. Schoenfeld MJ, Shortridge E, Cui Z, Muram D: Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med 2013, 10:1401–1409.
93. Donatucci C, Cui Z, Fang Y, Muram D: Long-term treatment patterns of testosterone replacement medications. J Sex Med 2014, 11:2092–2099.
94. Stout M, Tew GA, Doll H, Zwierska I, Woodroffe N, Chaner KS, Saxton JM: Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J 2012, 164:893–901.
95. Empen K, Lorbeer R, Donn M, Haring R, Nauck M, Glaser S, Krebs A, Rieffmann T, Ewert R, Volzke H, Wallaschekfai H, Felix SB: Association of testosterone levels with endothelial function in men: results from a population-based study. Antioxid Redox Signal 2012, 16:481–486.

Cite this article as: Borst et al.: Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Medicine 2014 12:211.